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Background: Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed cell death protein 1
(PD-1), anti-programmed death-ligand 1 (PD-L1), and/or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) can result in
impressive response rates and durable disease remission but only in a subset of patients with cancer. Expression of PD-L1 has
demonstrated utility in selecting patients for response to ICB and has proven to be an important biomarker for patient selection.
Tumor mutation burden (TMB) is emerging as a potential biomarker. However, refinement of interpretation and
contextualization is required.
Materials and methods: In this review, we outline the evolution of TMB as a biomarker in oncology, delineate how TMB can
be applied in the clinic, discuss current limitations as a diagnostic test, and highlight mechanistic insights unveiled by the study
of TMB. We review available data to date studying TMB as a biomarker for response to ICB by tumor type, focusing on studies
proposing a threshold for TMB as a predictive biomarker for ICB activity.
Results: High TMB consistently selects for benefit with ICB therapy. In lung, bladder and head and neck cancers, the current
predictive TMB thresholds proposed approximate 200 non-synonymous somatic mutations by whole exome sequencing (WES).
PD-L1 expression influences response to ICB in high TMB tumors with single agent PD-(L)1 antibodies; however, response may
not be dependent on PD-L1 expression in the setting of anti-CTLA4 or anti-PD-1/CTLA-4 combination therapy. Disease-specific
TMB thresholds for effective prediction of response in various other malignancies are not well established.
Conclusions: TMB, in concert with PD-L1 expression, has been demonstrated to be a useful biomarker for ICB selection across
some cancer types; however, further prospective validation studies are required. TMB determination by selected targeted panels
has been correlated with WES. Calibration and harmonization will be required for optimal utility and alignment across all
platforms currently used internationally. Key challenges will need to be addressed before broader use in different tumor types.
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Introduction
Currently, immune checkpoint blockade (ICB) therapy has
increased the overall survival (OS) rates of patients with advanced
melanoma, non-small-cell lung cancer (NSCLC), urothelial
cancer (UC), renal cell carcinoma (RCC), and other cancer types
[1–8]. Tumors often upregulate immune checkpoints to avoid
being detected and killed by the host immune system. Activation
of checkpoint cascades such as those controlled by programmed
cell death protein (PD-1) or CTLA-4 result in inactivation of
tumor-specific T cells and immune evasion [9–12]. Treatment
with anti-PD-1, anti-programmed death-ligand 1 (anti-PD-L1),
or anti-CTLA-4 reinvigorates T cells and allows the adaptive
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immune system to target tumor cells [13, 14]. Detection of tumor
and/or immune cell PD-L1 by immunohistochemical measure-
ment has been extensively studied as a predictor of response to
anti-PD(L)-1 treatment and has been convincingly demonstrated
to be a valid biomarker in some settings. PD-L1 expression by
immunohistochemistry (IHC) is an Food and Drug
Administration (FDA)-approved companion diagnostic test for
pembrolizumab in NSCLC, gastric/gastroesophageal junction
adenocarcinoma, cervical cancer and UC [15–20], and has shown
some predictive ability across several other cancer types including
head and neck and small-cell lung carcinoma [21–23].
PD-L1 quantitation for immunotherapy response prediction is
imperfect and there is a need for improved biomarkers of re-
sponse. The presence of tumor-infiltrating lymphocytes (TILs)
might confer a prognostic and a predictive impact [24, 25]. The
T-cell-inflamed gene expression profile (GEP) [26], immune
gene expression signatures [27, 28], as well as description of the
microbiome [29–31] also represent emerging predictive
biomarkers.
Cancer is a genetic disease. Neoplastic transformation results
from the accumulation of somatic mutations in the DNA of
affected cells. These genetic alterations include driver mutations,
mutations that directly affect tumor growth such as those in
TP53, epidermal growth factor receptor (EGFR) or RAS, and pas-
senger mutations, which are alterations that do not directly im-
pact the growth of the cancer cell [32–34]. Genetic changes in
tumors can include non-synonymous mutations largely com-
prised of missense mutations (point mutations that change the
amino acid codon), synonymous mutations (silent mutations
that do not alter amino acid coding), insertions or deletions
(indels, which can cause frameshifts), and copy number gains
and losses. There is dramatic variation in the frequency of each
type of these genetic alterations between individual tumors and
between different tumor types [35–38]. Tumor mutation burden
(TMB) can be used to predict ICB efficacy and has since become a
useful biomarker across many cancer types for identification of
patients that will benefit from immunotherapy [39–42].
TMB and its relationship to neoantigens
A minority of somatic mutations in tumor DNA can give rise to
neoantigens, mutation-derived antigens that are recognized and
targeted by the immune system, especially after treatment with
agents that activate T cells [39, 43–46]. These mutations can be
transcribed and translated, and neoantigen-containing peptides
can be processed by the antigen-processing machinery and
loaded on to major histocompatibility complex (MHC) mole-
cules for presentation on the cell surface. Importantly, however,
not all mutations will generate neoantigens. In fact, only a minor-
ity of mutations generate peptides that are properly processed
and loaded on to MHC complexes, and even fewer are able to be
recognized by T cells [47, 48]. Therefore, not all neopeptides pre-
sented on the cell surface are immunogenic [48–50].
Importantly, however, the more somatic mutations a tumor has,
the more neoantigens it is also likely to form, and TMB can repre-
sent a useful estimation of tumor neoantigenic load.
It is important to note that the presence of immunogenic neo-
antigens is not the only factor that influences the ability of T cells
to recognize and kill tumor cells. Inactivating mutations in the
antigen presentation pathway can occur, which can influence the
ability of cells to present peptides to the immune system. Some
immunologically relevant genes that can become mutated in can-
cers include JAK1, JAK2, B2M, STK11, and others [51, 52]. The
presence of these alterations can modulate the overall effect of
TMB or neoantigen load on ICB response.
Variation of TMB across tumor types
As TMB evolves as a relevant tool for the identification of patients
likely to respond to ICB, a large effort has been made to charac-
terize the type and the extent of TMB variation across tumor
types and histologies. Over the last few years, a large number of
studies have been able to map and characterize TMB variations
across disease pathologies [37, 38, 53], documenting the highest
levels of TMB in melanoma followed by NSCLCs and other squa-
mous carcinomas, while leukemias and pediatric tumors show
the lowest levels of TMB. Cancers such those of the breast, kidney,
and ovary display intermediate levels of mutational load. In add-
ition to the variation in the levels of TMB across tumor types, a
significant TMB range is also observed within the same cancer
type. Within NSCLCs, there is a high degree of variation in TMB
across patients attributable to smoking status compared with gas-
tric and breast cancers. Mutational signatures characterized by
Stratton et al. have shed light on the origins of tumor somatic
mutations [53]. For example, UV light and tobacco carcinogens
are the dominant mutational processes in melanoma and
NSCLC, respectively. Later in tumor evolution, mutations pre-
sent in some cells but not others (so-called subclonal mutations)
occur. In many tumor types, these mutations have been attrib-
uted to the APOBEC cytidine deaminase family and can also
occur following cytotoxic chemotherapy in resistant emergent
subclones [54–57]. The clonal nature of neoantigens has been
shown to be relevant for T cell priming and responses to immune
checkpoint inhibitors. Considering that intratumoral heterogen-
eity (ITH) can vary across tumor types [58] and can potentially
impact antitumor immunity, it is important to consider ITH
when analyzing TMB.
Variables defining TMB
Considering that high TMB correlates with a greater probability
of displaying tumor neoantigens on HLA molecules on the sur-
face of tumor cells [59, 60], it is rational to hypothesize that the
tumors with the highest TMB are more likely to respond to ICB
agents as this greater mutation load would increase the likelihood
of recognition by neoantigen-reactive T cells. Consistent with
this hypothesis, several studies have demonstrated an association
between high TMB and response to anti-CTLA-4 in melanoma
[39, 61] and anti-PD-1 in NSCLC [40]. Subsequent trials retro-
spectively analyzing TMB association with ICB treatment have
been conducted in NSCLC, small-cell lung cancer (SCLC), and
melanoma and have shown a correlation between TMB and ICB
benefit [41, 61–65]. Figure 1 shows the evolution of TMB as
an immunotherapy biomarker over the last several years.
Annals of Oncology Review
Volume 30 | Issue 1 | 2019 doi:10.1093/annonc/mdy495 | 45
TMB-based assays are currently being considered by the FDA for
approval as companion diagnostics for ICB agents.
For the initial studies, TMB was determined by whole exome
sequencing (WES) carried out on tumor DNA and matching nor-
mal DNA. Normal germline variations in DNA sequence between
individuals must be identified and removed from consideration
in order to tabulate only the somatic alterations, a process that
has been well-established [66, 67]. TMB is usually reported as the
total number of coding and somatic mutations, but in some
cases, can also include insertions and deletions (indels). Exonic
TMB is theoretically best measured by WES because this tech-
nique samples the entire exome. However, TMB by WES is not
yet routinely used as a clinical tool for predicting response to ICB
and is used for research only at this time largely due to its greater
cost and complexity.
Clinical WES is offered in Clinical Laboratory Improvement
Amendments (CLIA)-approved settings and active development
to bring these tests into the clinic is ongoing. Recent efforts have
begun to validate targeted NGS panels against WES data as these
panels are already being used routinely in clinic for oncogenic
mutation detection [37, 68]. With the Foundation Medicine
(FM) NGS approach (F1CDx), TMB was defined as the number
of base substitutions (including synonymous mutations) in the
coding region of targeted genes. Germline DNA was not
sequenced but filtering for both oncogenic driver events and
germline status was carried out using public and private variant
databases. The total mutations/megabase (mut/Mb) calculation
included both synonymous and non-synonymous mutations
requiring a bridging formula for conversion to number of mis-
sense mutations as determined by WES. The MSKCC NGS ap-
proach (MSK-IMPACT) tabulated non-synonymous mutations
using sequencing data from both tumor and germline DNA (for
variant calling). The most recent version of this panel sequences
468 genes covering 1.22 Mb. It has been shown that large targeted
panels are sufficiently accurate for TMB estimation [37, 69] and
panels tested to date (F1CDx and MSK-IMPACT), have demon-
strated their predictive ability for ICB response [4, 37, 70–73]
(Table 1). Both F1CDx and MSK-IMPACT have been approved
by the US FDA.
Several key variables need to be considered across platforms:
depth of sequencing, length of sequencing reads, choice of aligners,
variant callers, and filters used. They will all influence TMB meas-
urement (overview provided in Table 1). Preanalytical factors—
including sample collection and processing, input material quality
and quantity, fixation methodology, and library preparation—
affect the quantity and quality of DNA and thus shape TMB esti-
mation values. For example, fixatives and fixation time are preana-
lytical factors that influence the degree of formaldehyde fixed-
paraffin embedded (FFPE)-induced deamination artifacts, which
impact analysis of TMB counts. Also, low tumor purity, which can
result from sampling errors or a dense tumor microenvironment,
may lead to reduced TMB assay sensitivity.
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Figure 1. The evolution of tumor mutation burden as an immunotherapy biomarker. Major studies that are important in the development
of TMB as a biomarker are shown. Color coding indicates type of study. The studies are ordered as a function of time, with the year indicated
in the timeline. ICB, immune checkpoint blockade; 1L, ﬁrst line; 2L, second line; þ, and others; I-O, immune-oncology agent; IPI, ipilimumab;
NIVO, nivolumab; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; TMB, tumor mutational burden.
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Sequence coverage and read depth differ between WES and
targeted gene panel assays, with WES covering the entire exome
coding region and targeted gene panels variably covering pre-
specified territories of the exome or genome. Hence, the size and
location of the interrogated region differs between targeted gene
panel assays and requires careful consideration for accurate TMB
assessment (Figure 2). For example, confidence intervals for
TMB estimation increase with the use of gene panels that cover
only a small region of the genome/exome compared with those
that assess a larger area, suggesting that the use of small gene pan-
els can considerably over- or underestimate TMB [69, 74]. While
paired germline sequencing would reduce overall false positive
mutation calls, a dual analysis is not always carried out. In the
absence of such a comparison, large germline databases are
needed to reduce false positive mutation calling and identify
germline variants. Depth of sequencing also differs between WES
and targeted gene panel assays; sequencing depth is much higher
for targeted gene panels than for WES. Both coverage and
sequencing depth can determine assay sensitivity and specificity,
and therefore, influence TMB estimation output.
Bioinformatic algorithms strongly influence TMB estimation
and reporting. As they differ widely across gene panels platforms,
it is important that these specific procedures are transparent and
open to the scientific and medical community. For example, the
mutation types considered for TMB assessment can vary from
one assay to another. These may include or exclude short
Table 1. Key parameters for some TMB assays
Parameter WES FM NGS (F1CDx) MSKCC NGS (MSK-IMPACT)
No. of genes 22 000 gene coding regions 324 cancer-related genes 468 cancer-related genes
Types of mutations captured Coding missense mutations in
tumor genome
Coding, missense, and indel mutations
per Mb of tumor genome
Coding missense mutations per
Mb of tumor genome
Germline mutations Subtracted using patient-
matched normal samples
Estimated via bioinformatics algorithms
and subtracted
Subtracted using patient-
matched blood samples
Capture region (tumor DNA) 30 Mb 0.8 Mb 1.22 Mb
TMB deﬁnition No. of somatic, missense
mutations in the
sequenced tumor genome
No. of somatic, coding mutations (syn-
onymous and non-synonymous), short
indels per Mb of tumor genome
No. of somatic, missense muta-
tions per Mb of tumor
genome
WES, whole exome sequencing; FM, Foundation Medicine; NGS, next generation sequencing; Mb, megabase.
1 30
Subclonal sub
Clonal sub
indels
P1
P2
P3
P4
Variable 2
Variable 1
Variable 3
Exome  (coding region - approx. 1-2% of genome)-
1MB = 1 million nucleotides
Variability regarding definition
Figure 2. Target regions and sizes of four different hypothetical gene panels (P1–P4). Depending on the size and territory of the exome that
is captured by P1–P4, respectively, TMB counts will differ. Other parameters, e.g. ﬁltering of germline variants and cut points for allelic fre-
quencies (blue circles), discussed in this review will inﬂuence TMB measurement further.
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insertions and deletions (indels) and/or synonymous and nonsy-
nonymous base substitutions/single nucleotide variants. For
most retrospective analyses that employed WES, TMB was calcu-
lated from missense mutations only, leaving out indels and other
mutations, whereas some targeted approaches can include these
variant types. Moreover, cut points and filtering algorithms for
putative germline variants, variant allele frequency, and FFPE-
induced deamination artifacts may vary between assays and
can strongly impact TMB values. For example, variant allele
frequencies cut-offs can vary from 0.5% to 10%, with lower
thresholds increasing the risk of including false positives arising
from sequencing artifacts such as C to T transitions introduced
by formalin fixation.
TMB definition and correlation with
response to ICB
Before exploration of TMB as a biomarker, the expression of
PD-L1 in the tumor microenvironment was also being actively
investigated as a biomarker and demonstrated some success in
identifying patients most likely to benefit. PD-L1 quantitation
and has been approved as a companion diagnostic for pembroli-
zumab in NSCLC [75]. PD-L1 expression as a biomarker has
demonstrated an inconsistent record of enriching for response to
ICB, which is related to the dynamic and heterogeneous expres-
sion of PD-L1 in the tumor microenvironment, assay interpret-
ation, and a lack of standardization across PD-L1 platforms [76],
warranting the exploration of new biomarkers for patient selec-
tion. TMB will also raise similar practical points, as mentioned
previously for PD-L1, possibly with greater complexity and some
concerns for accessibility. Additionally, data suggest that TMB
will not replace other biomarkers such as IHC-based PD-L1 as-
sessment, but possibly complement them. Importantly, PD-L1
and TMB have consistently been shown to represent independ-
ent, not correlated, predictive variables [42, 68, 77–79].
The Checkmate 026 trial in first-line NSCLC comparing nivo-
lumab with standard of care (SOC) demonstrated no improve-
ment in the primary end point of progression-free survival (PFS)
in patients with PD-L1 expression 5% [42, 73]. Based on the
emerging phase II TMB data, DNA sequencing of tumors from
Checkmate 026 was carried out post hoc and yielded compelling
results. Patients with high TMB defined as those with tumors
with at least 243 missense mutations (the upper TMB tertile)
were found to have significantly improved PFS with nivolumab
treatment over SOC chemotherapy [hazard ratio (HR) 0.62]. A
caveat to this result is that all patients that underwent this TMB
analysis also had PD-L1 expression of 1%. Importantly,
patients with mutations in the lower 2/3 (less than 243 muta-
tions) had a worse PFS with nivolumab treatment compared with
SOC (HR 1.82), demonstrating the importance of low TMB as a
negative predictor of benefit in the context of effective SOC
options. Similarly, in UC, a phase III trial in platinum-treated
patients, IMvigor211, failed to meet its primary end point of OS
improvement with atezolizumab compared with SOC chemo-
therapy. Even with pre-specified PD-L1 selection, no improve-
ment in OS was demonstrated. Again, based on compelling phase
II TMB data in UC, a post hoc analysis of TMB employing a
threshold of 9.65 mut/Mb was conducted and showed a non-
significant but numerically improved OS (HR 0.68). Strikingly,
the subgroup of patients with both a high TMB and increased
PD-L1 (IC2/3) had an HR of 0.50 with atezolizumab treatment
[21].
Although TMB and PD-L1 do not co-associate in multiple tri-
als [42, 80, 81], greater benefit with single agent anti-PD-1 and
anti-PD-L1 is consistently observed with high TMB and PD-L1
expression, suggesting these independent biomarkers can be used
in concert [82, 83]. Given the high response rates when combin-
ing PD-L1 with CTLA-4 blockade in initial solid tumor studies,
there was speculation that patients with lower TMB tumors could
benefit by the addition of anti-CTLA-4 to anti-PD-1 but this was
not the case. In NSCLC, using a similar TMB threshold equiva-
lent to 200 missense mutations (10 mut/Mb), the benefit with
combination ICB was independent of PD-L1 expression in the
10 mut/Mb patient population [62]. A similar benefit that was
dependent on TMB but independent of PD-L1 expression was
observed in SCLC with nivolumab and ipilimumab in combin-
ation [62, 63]. These data are further supported in a phase III
NSCLC trial (Checkmate 227) comparing first-line
nivolumab þ ipilimumab with SOC chemotherapy [84]. This
study showed a significantly improved PFS in high TMB versus
SOC in both PD-L1 positive (HR 0.62) and negative (HR 0.48)
patients. The above observations suggesting that TMB, and not
necessarily PD-L1 status, associates with response to combin-
ation ICB (ipilimumab plus nivolumab) and is consistent with a
scenario where tumors with high TMB are potentially immuno-
genic but T-cell infiltration and/or activation is controlled in a
CTLA-4-dependent manner. This control can be either cell in-
trinsic by upregulation of CTLA-4 on effector T cells (Teff), or by
trans-regulation via CTLA-4hi regulatory T cells (Treg). Lack of
infiltration or T-cell activation would result in reduced IFN-c
within tumors, correlating with low or negative PD-L1 status at
diagnosis. Upon CTLA-4-blockade or anti-CTLA-4-driven Treg
depletion [85], re-activated effector T cells would upregulate PD-
1 and promote PD-L1 upregulation, hence explaining the synergy
with PD-1-blockade. Altogether, the previous supposition that
PD-L1 positive, inflamed tumors respond to ICB but PD-L1
negative, non-inflamed tumors do not require adjudication
based on the emerging data with TMB and combination im-
munotherapy (Figure 3).
Interestingly, TMB has also shown predictive value in im-
munotherapy modalities other than immune checkpoint blockde
therapy. Lauss et al. observed that tumor mutation and neoanti-
gen load predicted improved PFS and OS for melanoma patients
who were treated with adoptive T cell transfer therapy. This find-
ing suggests that greater numbers of potential neoantigens in
tumors may promote better clinical response to expanded and
reinfused TILs [86].
Is TMB ready to enter the clinic?
The first FDA approval based on the concept of mutation burden
was anti-PD1 therapy for patients with microsatellite instability-
high (MSI-H) cancers. MSI is one of a number of defects in DNA
repair that results in the accumulation of very high levels of TMB.
In the initial reports of anti-PD1 therapy in which multiple differ-
ent types of tumors were treated, only one of the 33 patients with
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colorectal cancer had an objective response to treatment [87, 88].
The discovery that this single responder had MSI-H colorectal
cancer led to successful prospective clinical trials of pembrolizu-
mab in adult and pediatric patients with MSI-H or DNA mis-
match repair-deficient (dMMR) solid tumors, and the rapid
approval of pembrolizumab in this biomarker-defined group of
patients [89, 90]. Importantly, this was the first tissue-agnostic
drug approval and the first approved companion biomarker assay
for any cancer therapy by the FDA [91, 92], and the approval
foretells a future in which tumor genomic analyses can be used to
personalize cancer immunotherapy. Although the majority of
patients with MSI-H solid tumors also have a high TMB, only
16% of patients with high TMB tumors are MSI-H [37]. Whereas
NSCLC might become one of the first indications for TMB appli-
cation as a biomarker (as a variable itself rather than via a surro-
gate-like MMR deficiency), MSI-H is extremely rare in this
entity.
Can the experience with MSI-H tumors be applied to MSI sta-
ble tumors? The median number of mutations in MSI-H tumors
is often in the thousands [89, 91], whereas in microsatellite stable
NSCLC, e.g. it is 200 mutations. Furthermore, the aggregate
data from multiple studies in SCLC, NSCLC, and UC approxi-
mate the TMB threshold required to enrich for benefit with ICB
(at least in high TMB tumors) to reside at 200 missense
mutations, which is equivalent to 10 mut/Mb by FoundationOne
testing or 7 mut/Mb by MSK-IMPACT testing [63, 70, 71, 73].
Employing higher thresholds of selection to 16.2 mut/Mb with
atezolizumab [80] and 15 mut/Mb with ipilimumab and nivolu-
mab [71] in NSCLC did not improve efficacy. Given the consist-
ent findings for these tumor types, one could envision the use of
TMB selection in the clinic for patient decision-making.
Checkmate 227 in first-line NSCLC was the first study to pro-
spectively include PFS in high TMB (10 mut/Mb) patients as a
co-primary end point. This trial demonstrated in TMB high
patients randomized to ipilimumab and nivolumab versus
chemotherapy a significant improvement in PFS (7.1 versus
3.2 months) and response rate (45.3% versus 24.6%) [84]. A
summary of the clinical data defining a TMB threshold with ICB
treatment is presented in Table 2. Several ongoing clinical trials
are using TMB as a key stratification factor or a landmark end
point (Table 3). They will help decipher the role of TMB in the
treatment decision process across cancer types and, by using dis-
tinct TMB thresholds and definitions, support a more refined
definition of TMB utility.
Some NGS assay providers have already nominated TMB
thresholds for certain applications. For example, the 10 mut/Mb
threshold (via F1CDx NGS assay) captures a significant fraction
of cancer patients and may be particularly useful to identify
 - Mutations (ultraviolet radiation, 
smoking, other carcinogens)
- Hereditary or acquired mismatch
repair deficiency (dMMR)
- Age related DNA replications errors
Somatic Mutations
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Figure 3. Mutations, neoantigens, and immune checkpoint blockade. Somatic mutations can generate neopeptides that are presented by
MHC molecules. Both inﬂamed and non-inﬂamed tumors, as well as PD-L1 positive or negative tumors, can respond to immune checkpoint
blockade therapy. TMB, tumor mutation burden; MMR, mismatch repair.
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cancer types with lower proportion of high TMB tumors, much
as MSI testing can currently accomplish (Figure 4). However,
applications to additional other tumor types will also require
their own threshold validation. This must be examined before ap-
plication to different malignancies. Furthermore, there is a need
for harmonization of TMB reporting across different NGS assays
currently in use and new NGS targeted assay platforms will also
require their own validation.
TMB limitations and perspectives
TMB is not without limitations. It is a relatively new type of bio-
marker, and defining standards for determination and reporting
of TMB are not well established. Proteins generated from gene
fusions and post-translational modifications of non-mutated
proteins are not accounted for in current iterations of TMB, but
nonetheless may contribute to neoantigenic load. More critically,
current iterations of the TMB assign an equal weight to each
tumor mutation, but it is increasingly clear that not all mutations
are created equal [53, 56]. Some mutations result in the forma-
tion of higher ‘quality’ antigens, which are more readily identified
as ‘non-self’ by the immune system and are more likely to induce
a robust antitumor immune response. Antigens resulting from
viral open reading frames in a cancer’s genome are an example of
a high-quality antigen. This may be the reason the subset of
Merkel-cell carcinoma that is associated with the Merkel-cell pol-
yomavirus has a moderate TMB [93] but amongst the highest re-
sponse rates of any tumor type with anti-PD1 therapy [94].
Another example of a tumor type with intermediate levels of
TMB but a high response rate to ICB is RCC [3, 95, 96]. Recent
work by Turajlic et al. shows that in addition to single nucleotide
Table 2. Key trials deﬁning a TMB threshold for ICB beneﬁt
Cancer Trial and treatment Method Threshold defined RR PFS OS Ref.
Melanoma Anti-CTLA-4 WES 100 mutations OS advantage [39]
Melanoma CM 038 WES 100 mutations OS advantage
in ipilimu-
mab naive
[64]
Phase II nivolumab
NSCLC KN 001 phase I/II WES 200 mutations 59% versus 12% NR versus 3.4
months
[40]
Pembrolizumab
NSCLC BIRCH, FIR phase II FM NGS 9.9 mut/Mb 25% versus 14% HR 0.64 HR 0.87 [70]
Atezolizumab
NSCLC POPLAR randomized phase II
atezolizumab versus docetaxel
FM NGS 9.9 mut/Mb 20% versus 4% 7.3 versus 2.8
months
16.2 versus 8.3
months
[70]
NSCLC MSKCC: various immunotherapies MSKCC NGS 7.4 mut/Mb 38.6% versus 25% [68]
NSCLC CM 012 WES 158 mutations 51% versus 13% 17.1 versus 3.7
months
[62]
Nivolumab/ipilimumab
NSCLC CM 568 FM NGS 10 mut/Mb 44% versus 12% 7.1 versus 2.6
months
[71]
Nivolumab/ipilimumab
SCLC CM 032 phase II nivolumab WES 248 mutations 46.2% versus 21.3% 7.8 versus 1.4
months
22 versus 5.4
months
[63]
versus nivolumab/ipilimumab
NSCLC CM 026 randomized phase III nivolumab
versus chemotherapy
WES >243 mutations 47% versus 23% HR 0.62 HR 1.10 [42]
NSCLC CM 227 randomized phase
III nivolumab/ipilimumab
versus chemotherapy
FM NGS >10 mut/Mb 45.3% versus 24.6% 7.1 versus 3.2
months
NA [77]
UC CM 275 phase II WES 170 versus
<85 mutations
31.9% versus 10.9% 3 versus 2
months
11.63 versus
5.72 months
[78]
Nivolumab
UC IMvigor210 phase II FM NGS 16 mut/Mb OS advantage [72]
Atezolizumab
UC IMVigor211 phase III FM NGS >9.65 mut/Mb HR 0.68 [73]
Atezolizumab versus chemotherapy
Solid tumor Various immunotherapies FM NGS 20 mut/Mb 58% versus 20% 12.8 versus 3.3
months
NR versus 16.3
months
[79]
Solid tumor KN 028 and KN 012 WES 102 mutations 30% versus 7% 109 versus 59
days
[81]
Pembrolizumab
HNSCC KN 012 and KN 055 pembrolizumab WES 175 mutations HR 0.64 HR 0.98 [83]
CM, checkmate; KN, keynote; NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer; UC, urothelial cancer; HNSCC, head and neck squamous cell
carcinoma; WES, whole exome sequencing; NGS, next generation sequencing; HR, hazard ratio; NA, not applicable; mut, mutation; FM, Foundation
Medicine.
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variants, frameshift mutations generated by insertion and dele-
tions that result in the generation of an entirely new peptide
amino acid chain before a stop codon being reached, also contrib-
ute to the generation of potent tumor neoantigens and the overall
TMB of cancers [97]. Interestingly, they demonstrated that RCCs
have the highest frequency and number of indel mutations across
cancer types. In MSI tumors, genetic instability manifests as short
indels resulting from lack of repair of slippages during replica-
tion. This, in MMR deficient tumors, indels may also need to be
considered in defining total TMB.
Another challenge is to understand how to use TMB while tak-
ing into account specific mutations that have been shown to in-
fluence response to ICB treatment. For example, mutations in
genes such as JAK1, JAK2, b2M, SKT11, SERPINB3, and
SERPINB4 have been shown to affect ICB response [51, 98].
Some mutations such as those in JAK1 and JAK2 are rare and do
not validate in all patient cohorts [64, 99]. Similarly, some im-
mune evasion mechanisms such as transforming growth factor b
(TGF-b) signaling [100] or indoleamine 2,3-dioxygenase (IDO)
activity may influence ICB response [101]. The importance of
these alterations will have to be tested in prospective trials. For
the variables that are currently validated as most useful, a model
taking into consideration TMB, individual mutations or pathways
that affect ICB outcomes, and PD-L1 levels—perhaps in the form
of a nonogram—could be developed to further improve predictive
models. Similar models are in use for predicting the likelihood of
disease control in patients with prostate cancer and for quantifying
benefit from chemotherapy for breast cancer patients [102–104]. It
should be noted that the use of expression signatures have had a
checkered past in the cancer biomarker field. Despite thousands of
expression signatures nominated for use as biomarkers, very few
have found reliable use in the clinic, especially when the expression
signatures do not correlate with reproducible genetic alterations.
Therefore, use of expression signatures in the immuno-oncology
setting needs to be carefully vetted. Indeed, the history of cancer
biomarker development suggests that genetic alterations and not
simply altered expression of a given target or pathway of interest,
which can often be reversible, are more robust predictors of re-
sponse to a therapy targeting that pathway. Despite expression of
IDO1 in tumors, genetic evidence that IDO is a cancer driver is
lacking. It is perhaps not surprising, then, that a recent large phase
III trial testing an IDO inhibitor in combination with anti-PD-1
did not shown benefit [105], leading to the widespread discontinu-
ation of IDO inhibitor development. However, some expression
signatures appear to be promising for detection of successful anti-
cancer immunity. Interestingly, Cristescu et al. show that TMB and
a T-cell inflamed gene expression signature can both provide pre-
dictive value for clinical response in patients treated on four
Keynote trials [26]. Furthermore, the utility of TMB and other bio-
markers noted above in patients treated with ICB plus chemother-
apy is unclear and will need to be studied. If TMB is predictive in
these settings, it is likely that new thresholds may need to be
established.
Regardless, building future algorithms for identifying
patients that will benefit from ICB will likely require assessment
of tumor and immune cells qualitatively and quantitatively.
TMB, specific mutations in oncogenes, as well as PD-L1 expres-
sion will describe the tumor component while immune cell PD-
L1 expression, HLA genotype, TCR repertoire, and possibly im-
mune signatures (as determined, e.g. by gene expression ana-
lysis) might be taken into account for the immune component
of response.
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Figure 4. Impact of TMB pan-cancer: percent of solid tumors with TMB 10 mut/Mb. Analysis of top 30 solid tumor types selected from
104,814 total cases sorted by percent of cases with TMB 10 mut/Mb according to the Foundation Medicine database. TMB is deﬁned as
the number of somatic synonymous and non-synonymous base substitutions and indels divided by the region over which it was counted.
Only cancer types with at least 100 total cases are reported. The average across all solid tumor types was 13.3%.
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Table 3. Ongoing clinical trials registered in ClinicalTrials.gov investigating immune checkpoint blockade in the context of TMB assessment
Trial name (NCT
number)
Phase Tumor type Therapy
1 MK-3475-016
(NCT01876511)
II MSI-positive or Pembrolizumab
MSI-negative CRC or other cancers
2 PRO 02 II Advanced solid tumors Multiple targeted therapies, including atezolizumab
(NCT02091141)
3 IMpower110 III NSCLC Atezolizumab versus chemotherapy
(NCT02409342)
4 OpACIN (NCT02437279) I Melanoma Adjuvant ipilimumabþnivolumab
5 CA209-260 II Melanoma or UC Nivolumab6ipilimumab
(NCT02553642)
6 TAPUR (NCT02693535) II Advanced solid tumors Multiple targeted therapies; including pembrolizumab and
nivolumabþipilimumab
7 AAAQ5450 II NSCLC Pembrolizumab6chemotherapy
(NCT02710396)
8 NCI-2016-00666 II Desmoplastic melanoma Pembrolizumab
(NCT02775851)
9 CheckMate 714 II SCCHN Ipilimumabþnivolumab
(NCT02823574)
10 MultiVir Ad-p53-001
(NCT02842125)
I/II Advanced solid tumors Adenoviral p53þpembrolizumab/nivolumab or chemotherapy
11 B-F1RST (NCT02848651) II NSCLC Atezolizumab
12 NCI-2016-01589 II NSCLC (EGFR-mutated) Multiple, including nivolumab and pembrolizumab
(NCT02949843)
13 OpACIN-neo II Melanoma Neoadjuvant ipilimumabþnivolumab
(NCT02977052)
14 NCI-2016-01698
(NCT02965716)
II Melanoma Pembrolizumabþtalimogene laherparepvec (virus therapy)
15 PEER (NCT02990845) I/II Breast Pembrolizumabþexemestane (aromatase inhibitor)þleuprolide
(anti-GnRH)
16 ULTIMATE II Breast Tremelimumabþdurvalumabþexemestane (aromatase inhibitor)
(NCT02997995)
17 CL-PTL-126 II Gynecological cancers Atezolizumabþvigil (immuno-stimulatory autologous cellular
therapy)(NCT03073525)
18 CA209-777 (NCT03091491) II NSCLC (EGFR mutant positive) Nivolumab6ipilimumab
19 ISABR I/II NSCLC Durvalumabþradiation
(NCT03148327)
20 CMIW815X2102J
(NCT03172936)
1 Advanced solid tumors and
lymphomas
PDR001 (anti-PD-1) þ MIW815/ADU-S100 (IFN genes stimulator)
21 B-FAST II/III NSCLC Atezolizumab versus chemotherapy
(NCT03178552)
22 KELLY (NCT03222856) II Breast (HRþ/HER2 subtype) Pembrolizumabþchemotherapy
23 RESPONDER II UC Pembrolizumab
(NCT03263039)
24 IFG-NIB-01 (NCT03289819) II Breast (triple negative subtype) Pembrolizumabþchemotherapy
25 NET-002 (NCT03278379) II Neuroendocrine Avelumab
26 B9991023 II NSCLC, UC Avelumabþchemotherapy
(NCT03317496)
27 CA209-929 II Breast, ovarian, gastric Ipilimumabþnivolumab
(NCT03342417)
28 Javelin Parp Medley
(NCT03330405)
Ib/II Advanced solid tumors Avelumabþtalazoparib (anti-PARP)
29 R2810-ONC-1763 II NSCLC Cemiplimab (anti-PD-1)6ipilimumab
(NCT03430063)
30 NIVES (NCT03469713) II RCC Nivolumabþradiotherapy
31 Javelin Medley VEGF
(NCT03472560)
II NSCLC, UC Avelumabþaxitinib (TKI)
Continued
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Discussion
Conclusions
The relationship between TMB and response to immune check-
point inhibitors is paving the way towards a precision immuno-
genetics approach to cancer treatment. From the initial clinical
observations associating tumors with genetic damage from envir-
onmental factors, we have begun a journey of discovery that will
greatly broaden the scope and practice of precision oncology.
TMB and other genetic determinants of response to immuno-
therapy have already provided exciting new avenues to make can-
cer treatment more precise. Nevertheless, challenges remain. Our
knowledge of how genetics shapes immune response in unclear
and this gap in knowledge must be bridged in order to build even
better predictive models. How TMB can be used in combination
with PD-L1 quantitation or measures of tumor inflammation
needs to be improved. Moreover, the impact of how HLA geno-
type and other germline variations influences the effect of TMB
and response to ICB needs to be explored further [106]. Lastly, as
discussed above, we highlight the need for cross-assay standard-
ization of NGS methods and solidification of interpretation of
TMB levels in order to ensure reliable treatment decisions in the
clinic based on tumor genetics.
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